Judit Garcia Gonzalez

Dr. Judit Garcia Gonzalez


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2023 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
SCShing Wan Choi
Shing Wan Choi
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
YRYunfeng Ruan
Yunfeng Ruan
HWHei Man Wu
Hei Man Wu
CPChristian Porras
Christian Porras
POPaul F. O’reilly
Paul F. O’reilly
Polygenic risk scores (PRSs) have been among the leading advances in biomedicine in recent years. As a proxy of genetic liability, PRSs are utilised across multiple fields and applications. While numerous statistical and machine learning methods have been developed to optimise their predictive accuracy, these typically distil genetic liability to a single number based on aggregation of an individual’s genome-wide risk alleles. This results in a key loss of information about an individual’s genetic profile, which could be critical given the functional sub-structure of the genome and the heterogeneity of complex disease. In this manuscript, we introduce a ‘pathway polygenic’ paradigm of disease risk, in which multiple genetic liabilities underlie complex diseases, rather than a single genome-wide liability. We describe a method and accompanying software, PRSet, for computing and analysing pathway-based PRSs, in which polygenic scores are calculated across genomic pathways for each individual. We evaluate the potential of pathway PRSs in two distinct ways, creating two major sections: (1) In the first section, we benchmark PRSet as a pathway enrichment tool, evaluating its capacity to capture GWAS signal in pathways. We find that for target sample sizes of >10,000 individuals, pathway PRSs have similar power for evaluating pathway enrichment as leading methods MAGMA and LD score regression, with the distinct advantage of providing individual-level estimates of genetic liability for each pathway -opening up a range of pathway-based PRS applications, (2) In the second section, we evaluate the performance of pathway PRSs for disease stratification. We show that using a supervised disease stratification approach, pathway PRSs (computed by PRSet) outperform two standard genome-wide PRSs (computed by C+T and lassosum) for classifying disease subtypes in 20 of 21 scenarios tested. As the definition and functional annotation of pathways becomes increasingly refined, we expect pathway PRSs to offer key insights into the heterogeneity of complex disease and treatment response, to generate biologically tractable therapeutic targets from polygenic signal, and, ultimately, to provide a powerful path to precision medicine.

5 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
PFPatricia Forcén
Patricia Forcén
MJMaria Jimenez-Sanchez
Maria Jimenez-Sanchez
There is extensive evidence of gender inequality in research leading to insufficient representation of women in leadership positions. Numbers revealing a gender gap in research are periodically reported by national and international institutions but data on perceptions of gender equality within the research community are scarce. In the present study, a questionnaire based on the British Athena Survey of Science, Engineering and Technology (ASSET 2016) was distributed among researchers working in Spain. Consistent with the original UK-based study, women in research perceived a greater degree of gender inequality than men. This difference was consistent from junior to senior positions, within public and private universities as well as research centres, and across all research disciplines. When responses were compared with the existing UK-based questionnaire, researchers in Spain felt that women and men are treated more equally in the workplace, yet they perceived their home departments to be less supportive regarding matters of gender equality. The results of this study provide clear evidence that men and women do not share the same perceptions of gender equality in science and that their differing perceptions are relatively consistent across two major European countries. The fact that men occupy the majority of senior positions while not perceiving the same inequality as women do, may be critical when it comes to ensuring the fair ascent of women to senior positions in an academic system. These data encourage the implementation of measures to ensure that both men and women are aware of gender biases in research.

1 April 2017 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Open access
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
KTKatherine E. Tansey
Katherine E. Tansey
JHJoanna Hauser
Joanna Hauser
NHNeven Henigsberg
Neven Henigsberg
WMWolfgang Maier
Wolfgang Maier
CFChiara Fabbri
Chiara Fabbri
Major depressive disorder (MDD) has a high personal and socio-economic burden and >60% of patients fail to achieve remission with the first antidepressant. The biological mechanisms behind antidepressant response are only partially known but genetic factors play a relevant role. A combined predictor across genetic variants may be useful to investigate this complex trait. Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) antidepressant efficacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and tested whether these predicted symptom improvement or remission from the GENDEP study (n=736) to the STAR*D study (n=1409) and vice-versa, including the whole sample or only patients treated with escitalopram or citalopram. Using summary statistics from Psychiatric Genomics Consortium for MDD and schizophrenia, we tested whether PRS from these disorders predicted symptom improvement in GENDEP, STAR*D, and five further studies (n=3756). No significant prediction of antidepressant efficacy was obtained from PRS in GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence of overlap in the genetics of antidepressant response with either MDD or schizophrenia, either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the results. We identified no significant predictive effect using PRS between pharmacogenetic studies. The genetic liability to MDD or schizophrenia did not predict response to antidepressants, suggesting differences between the genetic component of depression and treatment response. Larger or more homogeneous studies will be necessary to obtain a polygenic predictor of antidepressant response.

20 December 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CHClive J. Hoggart
Clive J. Hoggart
SCShing Wan Choi
Shing Wan Choi
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
TSTade Souaiaia
Tade Souaiaia
MPMichael Preuss
Michael Preuss
POPaul F. O’rEilly
Paul F. O’rEilly
Here we present BridgePRS, a novel Bayesian polygenic risk score (PRS) method that leverages shared genetic effects across ancestries to increase PRS portability. We evaluate BridgePRS via simulations and real UK Biobank data across 19 traits in individuals of African, South Asian and East Asian ancestry, using both UK Biobank and Biobank Japan genome-wide association study summary statistics; out-of-cohort validation is performed in the Mount Sinai (New York) BioMe biobank. BridgePRS is compared with the leading alternative, PRS-CSx, and two other PRS methods. Simulations suggest that the performance of BridgePRS relative to PRS-CSx increases as uncertainty increases: with lower trait heritability, higher polygenicity and greater between-population genetic diversity; and when causal variants are not present in the data. In real data, BridgePRS has a 61% larger average R2 than PRS-CSx in out-of-cohort prediction of African ancestry samples in BioMe (P = 6 × 10−5). BridgePRS is a computationally efficient, user-friendly and powerful approach for PRS analyses in non-European ancestries.

1 February 2019 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
OMOuti Mantere
Outi Mantere
KTKalevi Trontti
Kalevi Trontti
JGJudit Garcia Gonzalez
Judit Garcia Gonzalez
IBIngrid Balcells
Ingrid Balcells
SSSuvi Saarnio
Suvi Saarnio
Jaana SuvisaariJaana Suvisaari
Jaana Suvisaari

20 March 2014 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CACristina Aguado
Cristina Aguado
MGMagdalena Gayà-Vidal
Magdalena Gayà-Vidal
SVSergi Villatoro
Sergi Villatoro
MOMeritxell Oliva
Meritxell Oliva
DIDavid Izquierdo
David Izquierdo
Mario CáceresMario Cáceres
Mario Cáceres
In recent years different types of structural variants (SVs) have been discovered in the human genome and their functional impact has become increasingly clear. Inversions, however, are poorly characterized and more difficult to study, especially those mediated by inverted repeats or segmental duplications. Here, we describe the results of a simple and fast inverse PCR (iPCR) protocol for high-throughput genotyping of a wide variety of inversions using a small amount of DNA. In particular, we analyzed 22 inversions predicted in humans ranging from 5.1 kb to 226 kb and mediated by inverted repeat sequences of 1.6–24 kb. First, we validated 17 of the 22 inversions in a panel of nine HapMap individuals from different populations, and we genotyped them in 68 additional individuals of European origin, with correct genetic transmission in ∼12 mother-father-child trios. Global inversion minor allele frequency varied between 1% and 49% and inversion genotypes were consistent with Hardy-Weinberg equilibrium. By analyzing the nucleotide variation and the haplotypes in these regions, we found that only four inversions have linked tag-SNPs and that in many cases there are multiple shared SNPs between standard and inverted chromosomes, suggesting an unexpected high degree of inversion recurrence during human evolution. iPCR was also used to check 16 of these inversions in four chimpanzees and two gorillas, and 10 showed both orientations either within or between species, providing additional support for their multiple origin. Finally, we have identified several inversions that include genes in the inverted or breakpoint regions, and at least one disrupts a potential coding gene. Thus, these results represent a significant advance in our understanding of inversion polymorphism in human populations and challenge the common view of a single origin of inversions, with important implications for inversion analysis in SNP-based studies. Inversions have been an evolutionary biology model for almost a century, and recently the discovery of a high amount of structural variation in multiple organisms, including humans, has renewed the interest in them. Since early on, it was shown that they were adaptive and that they were involved in human diseases. However, in humans, the study of inversions has lagged behind due to important limitations in the experimental methods to analyze them. Here, we have optimized a technique for high-throughput validation and genotyping of inversions mediated by inverted repeats. By genotyping 17 of these inversions in a diverse sample of human individuals, including many of European origin and several non-human primates, we have carried out the most complete genotyping effort of human inversions to date. The results of our study indicate that a high proportion of these inversions are recurrent and have occurred multiple times during evolution. This represents an example of the plasticity of the genome and opens a new paradigm in the study of inversions, challenging the common view that inversions have a unique origin.